RE:RE:RE:RE:RE:Can you educate me on bondstruestar. You are obviously a novice on this stock. Buyers have looked at it when strategic review started in April and left because the debt was more than the assets. Now they have 350 million more debt and their assets in the past two quarters have declined. We now have issues over the pond with the nhs and cma investigation as well as a class action law suit which has stated SEC violations. You obviously just stepped into this stock and think that because you heard Trump is good for pharma that it will solve this company's problems that have been developing for quite some time. If Apollo was interested, and I say a big "IF", they were pricing assets in bankruptcy because since then Brexit happened and two brutal quarters with a large part of the north american assets being written off under impairments. Now I'm not trying to be cruel here, but the same story of pe now being interested just because hiliary wasn't elected is not reasonable because in april there wasn't the problems in the uk and that has been the shining star so far with the drug sales. The N. american drugs are al at the end of their life and that is showing in the volume of sales. So nobody is interested in those because they aren't even on patent any more. With AMCo's drugs there maybe more interest but there is regulatory problems there now since Apolo looked. So to answer your question, it is less likely now that PE is interested because it was the AMCo assets that looked attractive in April. I agree that people hop on getting all excited when they see the price increasing because they fear missing out. And then poof, you are sitting at the end of the week like I have done many times saying why didn't I get rid of this stock that torments me week after week. Its called volatility. Don't read too much into it.